Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Spyre Therapeutics (SYRE) Return on Sales (2016 - 2024)

Spyre Therapeutics' Return on Sales history spans 9 years, with the latest figure at 529.4% for Q1 2024.

  • For Q1 2024, Return on Sales fell 43636.0% year-over-year to 529.4%; the TTM value through Mar 2024 reached 529.4%, down 46261.0%, while the annual FY2023 figure was 382.38%, 34639.0% down from the prior year.
  • Return on Sales reached 529.4% in Q1 2024 per SYRE's latest filing, down from 382.38% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.57% in Q2 2021 to a low of 529.4% in Q1 2024.
  • Average Return on Sales over 4 years is 156.5%, with a median of 98.92% recorded in 2022.
  • Peak YoY movement for Return on Sales: crashed -3515bps in 2022, then crashed -43636bps in 2024.
  • A 4-year view of Return on Sales shows it stood at 5.61% in 2021, then plummeted by -1897bps to 112.04% in 2022, then crashed by -241bps to 382.38% in 2023, then tumbled by -38bps to 529.4% in 2024.
  • Per Business Quant, the three most recent readings for SYRE's Return on Sales are 529.4% (Q1 2024), 382.38% (Q4 2023), and 279.35% (Q3 2023).